Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma

X
Trial Profile

A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amdizalisib (Primary) ; Tazemetostat (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Peripheral T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors HUTCHMED
  • Most Recent Events

    • 17 May 2024 According to a HUTCHMED media release, data from this study will be presented at the upcoming European Hematology Association (EHA) Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online.
    • 12 Sep 2023 According to a HUTCHMED media release, the first patient was dosed in February 2023.
    • 15 Feb 2023 Planned initiation date changed from 1 Feb 2023 to 13 Feb 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top